In Part 2 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how policy and regulation are redefining pricing, access, and market stability.

We've been keeping Eyes On Regulatory news, both in the US and Europe. We're sharing a few of the updates from the past few weeks on approval timing, staffing changes, clinical results, international company coalitions, and more.